AMR Benchmark homepage
The superbugs can be stopped - if we put good ideas into action
The AMR Benchmark: 1st report on pharma’s response to AMR
The Antimicrobial Resistance Benchmark compares how pharmaceutical companies are bringing AMR under control. It covers R&D, responsible manufacturing, access and stewardship.
28 antibiotics for priority pathogens - two stand out
The pipelines captured in the Benchmark have 175 antimicrobial medicines targeting pathogens seen by WHO and CDC as the biggest AMR threats, including 28 antibiotic candidates in late stages of clinical development.
Nine companies are tracking drug resistance
Curbing AMR depends on knowing where pathogens are developing resistance. Nine companies are running or supporting 19 AMR surveillance programmes across 147 countries.
News related to the Antimicrobial Resistance Benchmark
"There are real solutions for slowing AMR. By identifying which pharmaceutical companies are taking action, we can help good ideas to spread."
Jayasree K. Iyer
Executive Director Access to Medicine Foundation
View our detailed overview of each company’s performance